Trial Profile
Primary Treatment of Macroglobulinemic Lymphoma With 2CdA [cladribine], Cyclophosphamide and Rituximab
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2022
Price :
$35
*
At a glance
- Drugs Cladribine (Primary) ; Cyclophosphamide (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 03 Mar 2022 Status changed from active, no longer recruiting to completed.
- 15 Jan 2020 Planned End Date changed from 1 Jul 2019 to 31 Jul 2020.
- 15 Jan 2020 Planned primary completion date changed from 1 Jul 2019 to 31 Jul 2020.